PASG

Passage Bio Inc

Add to Watchlist

Advanced Chart

5.670

+0.4(7.590%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.860

Open

5.320

VWAP

5.51

Vol

140.48K

Mkt Cap

17.69M

Low

5.320

Amount

774.42K

EV/EBITDA(TTM)

Total Shares

61.64M

-46.01M

EV/OCF(TTM)

P/S(TTM)

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-3.150

-21.25%

-4.050

-14.01%

-4.150

-20.19%

Estimates Revision

The market is revising No Change the revenue expectations for Passage Bio, Inc. (PASG) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -19.00%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+25.97%

In Past 3 Month

Stock Price

Go Down

-19.00%

In Past 3 Month

5 Analyst Rating

5.82% Upside

Wall Street analysts forecast PASG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PASG is 6.00 USD with a low forecast of 2.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

5.82% Upside

Current: 5.670

Low

2.00

Averages

6.00

High

13.00

5.82% Upside

Current: 5.670

Low

2.00

Averages

6.00

High

13.00

Guggenheim

Debjit Chattopadhyay

Buy

downgrade

$4 -> $2

2025-05-20

Reason

Guggenheim

Debjit Chattopadhyay

Price Target

$4 -> $2

2025-05-20

downgrade

Buy

Reason

Guggenheim analyst Debjit Chattopadhyay lowered the firm's price target on Passage Bio to $2 from $4 and keeps a Buy rating on the shares after updating the firm's models following Q1 results. The firm revised its 2025 projections to reflect the 55% workforce reduction in January, leading to lower R&D and SG&A expense estimates, adding that it believes Passage will need to raise capital and increase its share count in the near future.

Chardan Capital

Geulah Livshits

Strong Buy

Maintains

$7 → $6

2025-03-04

Reason

Chardan Capital

Geulah Livshits

Price Target

$7 → $6

2025-03-04

Maintains

Strong Buy

Reason

Chardan lowered the firm's price target on Passage Bio to $6 from $7 and keeps a Buy rating on the shares. The firm updated the company's model for the Q4 report. Data from patients treated with dose 1 of PBFT02 continue to look encouraging in frontotemporal dementia with GRN mutations, with patient dosing underway for a lower dose, the analyst tells investors in a research note. The firm sees upcoming catalysts for the shares, including updated data from the trial in the second half of 2025.

Wedbush

Yun Zhong

Buy

Initiates

2024-11-29

Reason

Wedbush

Yun Zhong

Price Target

2024-11-29

Initiates

Buy

Reason

Chardan Capital

Geulah Livshits

Strong Buy

Maintains

2024-11-14

Reason

Chardan Capital

Geulah Livshits

Price Target

2024-11-14

Maintains

Strong Buy

Reason

Canaccord Genuity

Whitney Ijem

Strong Buy

Maintains

$13

2024-11-14

Reason

Canaccord Genuity

Whitney Ijem

Price Target

$13

2024-11-14

Maintains

Strong Buy

Reason

Canaccord Genuity

Whitney Ijem

Strong Buy

Reiterates

$13

2024-09-17

Reason

Canaccord Genuity

Whitney Ijem

Price Target

$13

2024-09-17

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Passage Bio Inc (PASG.O) is -0.38, compared to its 5-year average forward P/E of -2.04. For a more detailed relative valuation and DCF analysis to assess Passage Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.04

Current PE

-0.38

Overvalued PE

0.14

Undervalued PE

-4.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.26

Current EV/EBITDA

0.30

Overvalued EV/EBITDA

1.48

Undervalued EV/EBITDA

-1.99

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.64

Current PS

0.00

Overvalued PS

7.64

Undervalued PS

-4.36